pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of an investigational DNA vaccine,
pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with
nivolumab, and the efficacy of this combination in decreasing serum Prostate-Specific Antigen
(PSA) in patients with non-metastatic, non-castrate prostate cancer (clinical stage D0/M0).
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
AIQ Solutions Bristol-Myers Squibb Madison Vaccines Inc. (MVI) National Cancer Institute (NCI)